stockrowRoivant Sciences Ltd.
ROIV Healthcare Biotechnology
Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.
- Revenue
- −33.6%
- EPS
- +21.2%
- Free cash flow
- −30.0%
Quarter to June 2026, against a year earlier
Follow ROIV
Alert me
Roivant Sciences Ltd. (ROIV) Gross margin
Roivant Sciences Ltd.'s gross margin over the twelve months to 30 June 2026 was 81.2%, down 3.2 percentage points from fiscal 2026 (84.4%). Over the past ten years it has ranged from 78.6% (fiscal 2023) to 96.9% (fiscal 2025); the current reading is higher than 50% of that period. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2026 | 84.4% | (12.42) |
| FY2025 | 96.9% | 1.75 |
| FY2024 | 95.1% | 16.53 |
| FY2023 | 78.6% | (5.20) |
| FY2022 | 83.8% | (7.58) |
| FY2021 | 91.4% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | 80.3% | (6.99) |
| Mar 2026 | 87.3% | 22.32 |
| Dec 2025 | 65.0% | (27.95) |
| Sep 2025 | 92.9% | 0.03 |
| 21 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| RPRX Royalty Pharma PLC compare | 100.0% |
| RVMD Revolution Medicines, Inc. compare | 95.6% |
| GMAB Genmab A/S Sponsored ADR compare | 93.0% |
| INCY Incyte Corporation compare | 92.7% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 89.4% |
| INSM Insmed, Inc. compare | 84.4% |
| ROIV Roivant Sciences Ltd. | 81.2% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 77.3% |
| BNTX BioNTech SE Sponsored ADR compare | 74.6% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on ROIV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement